uric acid has been researched along with Bone Loss, Perimenopausal in 12 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although the positive correlation between serum uric acid (UA) levels and bone mineral density (BMD) has been reported in the general population, there are little data regarding the effect of serum UA levels on bone loss in patients with rheumatoid arthritis (RA)." | 7.96 | Higher serum uric acid levels are associated with reduced risk of hip osteoporosis in postmenopausal women with rheumatoid arthritis. ( Kim, A; Kim, GT; Kim, Y; Lee, HN; Lee, SG; Sohn, DH, 2020) |
| "Although the positive correlation between serum uric acid (UA) levels and bone mineral density (BMD) has been reported in the general population, there are little data regarding the effect of serum UA levels on bone loss in patients with rheumatoid arthritis (RA)." | 3.96 | Higher serum uric acid levels are associated with reduced risk of hip osteoporosis in postmenopausal women with rheumatoid arthritis. ( Kim, A; Kim, GT; Kim, Y; Lee, HN; Lee, SG; Sohn, DH, 2020) |
| "When calcium citrate was combined with potassium citrate, urinary calcium remained high, urinary citrate increased even further and urinary oxalate remained reduced from the calcium citrate alone, thereby marginally decreasing the urinary saturation of calcium oxalate." | 2.71 | Stone forming risk of calcium citrate supplementation in healthy postmenopausal women. ( Griffith, CS; Pak, CY; Poindexter, JR; Sakhaee, K, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, HN | 1 |
| Kim, A | 1 |
| Kim, Y | 1 |
| Kim, GT | 1 |
| Sohn, DH | 1 |
| Lee, SG | 1 |
| Zhao, X | 1 |
| Yu, X | 1 |
| Zhang, X | 1 |
| Han, W | 2 |
| Bai, X | 2 |
| Han, L | 2 |
| Sun, X | 2 |
| Chen, X | 2 |
| Wang, N | 1 |
| Yan, DD | 1 |
| Wang, J | 2 |
| Hou, XH | 1 |
| Bao, YQ | 1 |
| Zhang, ZL | 1 |
| Hu, C | 1 |
| Jia, WP | 1 |
| Ishii, S | 1 |
| Miyao, M | 1 |
| Mizuno, Y | 1 |
| Tanaka-Ishikawa, M | 1 |
| Akishita, M | 1 |
| Ouchi, Y | 1 |
| Dalbeth, N | 1 |
| Gamble, GD | 1 |
| Horne, A | 1 |
| Reid, IR | 1 |
| Pirro, M | 1 |
| Mannarino, MR | 1 |
| Bianconi, V | 1 |
| De Vuono, S | 1 |
| Sahebkar, A | 1 |
| Bagaglia, F | 1 |
| Franceschini, L | 1 |
| Scarponi, AM | 1 |
| Mannarino, E | 1 |
| Merriman, T | 1 |
| Black, DM | 1 |
| Greenspan, SL | 1 |
| Ensrud, KE | 1 |
| Palermo, L | 1 |
| McGowan, JA | 1 |
| Lang, TF | 1 |
| Garnero, P | 1 |
| Bouxsein, ML | 1 |
| Bilezikian, JP | 1 |
| Rosen, CJ | 1 |
| Sakhaee, K | 1 |
| Poindexter, JR | 1 |
| Griffith, CS | 1 |
| Pak, CY | 1 |
| Deal, C | 1 |
| Omizo, M | 1 |
| Schwartz, EN | 1 |
| Eriksen, EF | 1 |
| Cantor, P | 1 |
| Glass, EV | 1 |
| Myers, SL | 1 |
| Krege, JH | 1 |
| Yanik, B | 1 |
| Bavbek, N | 1 |
| Yanik, T | 1 |
| Inegöl, I | 1 |
| Kanbay, M | 1 |
| Turgut, FH | 1 |
| Uz, E | 1 |
| Akçay, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Trial of Parathyroid Hormone (PTH) and Alendronate in Combination in the Treatment of Osteoporosis[NCT00005005] | Phase 2 | 238 participants (Actual) | Interventional | 1999-10-31 | Completed | ||
| The Denosumab And Teriparatide Administration Study (DATA)[NCT00926380] | Phase 2 | 94 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00926380)
Timeframe: Baseline and 2 years
| Intervention | percent change (Mean) |
|---|---|
| Denosumab ONLY | 8.3 |
| Teriparatide (Forteo®) ONLY | 9.5 |
| Denosumab and Teriparatide (Forteo®) | 12.9 |
5 trials available for uric acid and Bone Loss, Perimenopausal
| Article | Year |
|---|---|
Relationship Between Changes in Serum Urate and Bone Mineral Density During Treatment with Thiazide Diuretics: Secondary Analysis from a Randomized Controlled Trial.
Topics: Aged; Bone Density; Double-Blind Method; Female; Humans; Hydrochlorothiazide; Middle Aged; Osteoporo | 2016 |
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Remodel | 2003 |
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Remodel | 2003 |
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Remodel | 2003 |
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Remodel | 2003 |
Stone forming risk of calcium citrate supplementation in healthy postmenopausal women.
Topics: Aged; Calcium; Calcium Citrate; Calcium Phosphates; Citric Acid; Dietary Supplements; Drug Therapy, | 2004 |
Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Bone Density; Calcium; Collagen; Collagen Type I; Creatine; Double-Blind Me | 2005 |
The effect of alendronate, risedronate, and raloxifene on renal functions, based on the Cockcroft and Gault method, in postmenopausal women.
Topics: Aged; Alendronate; Bone Density Conservation Agents; C-Reactive Protein; Calcium; Etidronic Acid; Fe | 2007 |
7 other studies available for uric acid and Bone Loss, Perimenopausal
| Article | Year |
|---|---|
Higher serum uric acid levels are associated with reduced risk of hip osteoporosis in postmenopausal women with rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Cross-Sectional Studies; Female; Humans; Middle Aged; Osteoporosis, Pos | 2020 |
Association between Uric Acid and Bone Mineral Density in Postmenopausal Women with Type 2 Diabetes Mellitus in China: A Cross-Sectional Inpatient Study.
Topics: Age Factors; Aged; Aged, 80 and over; Body Mass Index; Bone Density; China; Cross-Sectional Studies; | 2020 |
Association between higher serum uric acid levels within the normal physiological range and changes of lumbar spine bone mineral density in healthy Chinese postmenopausal women: a longitudinal follow-up study.
Topics: Absorptiometry, Photon; Bone Density; China; Female; Follow-Up Studies; Humans; Longitudinal Studies | 2021 |
Association between lumbar bone mineral density and serum uric acid in postmenopausal women: a cross-sectional study of healthy Chinese population.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Body Mass Index; Bone Density; Bone Diseases, Metab | 2017 |
Association of serum uric acid levels with osteoporosis and bone turnover markers in a Chinese population.
Topics: Aged; Asian People; Biomarkers; Bone Remodeling; China; Collagen Type I; Female; Humans; Male; Middl | 2018 |
Association between serum uric acid and lumbar spine bone mineral density in peri- and postmenopausal Japanese women.
Topics: Aged; Aging; Bone Density; Female; Humans; Lumbar Vertebrae; Menopause; Middle Aged; Osteoporosis, P | 2014 |
Uric acid and bone mineral density in postmenopausal osteoporotic women: the link lies within the fat.
Topics: Adiposity; Aged; Aged, 80 and over; Alkaline Phosphatase; Anthropometry; Biomarkers; Bone and Bones; | 2017 |